激素缓释系统治疗糖尿病性黄斑水肿的研究进展  

Recent advances in corticosteroids for diabetic macular edema

作　　者：薛媛媛 陈晓隆[1] Xue Yuanyuan;Chen Xiaolong(The Shengjing Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属盛京医院,沈阳110001

出　　处：《临床眼科杂志》2021年第5期470-474,共5页Journal of Clinical Ophthalmology

基　　金：国家自然科学基金项目(81570866)。

摘　　要：糖尿病性黄斑水肿(DME)是糖尿病患者视力丧失的重要原因。目前,抗血管内皮生长因子(VEGF)药物及激光光凝是治疗DME的主要手段,但术后仍有部分患者无反应或反应欠佳。激素不仅能减少VEGF的表达,还可抑制炎症因子的分泌,作用途径更加丰富。并有大量研究证实,其他治疗无效的DME改用激素治疗可取得较好的疗效。近些年来,激素缓释系统因长期平稳释放药物的优势,受到广泛关注。但术后存在白内障加重、眼压升高等并发症,仅在某些特定情况下作为首选方案。本文就激素玻璃体腔给药治疗DME的研究现状进行阐述。Diabetic macular edema(DME)is an important cause of vision decline in patients with diabetes mellitus.At present,anti-VEGF and laser photocoagulation are the main methods for the treatment of DME,but some patients have poor response.Corticosteroids can not only reduce the expression of VEGF,but also inhibit the secretion of inflammatory factors.A large number of studies have also confirmed that corticosteroids can achieve better therapeutic effects on DME which is ineffective in other treatments.In recent years,sustained-release hormone system has been widely favored due to its advantages of long-term stable release of drugs.However,there are complications such as cataract aggravation and intraocular pressure elevation.In this paper,the research advances in intravitreal corticosteroid drug for DME is described.

关 键 词：糖尿病性黄斑水肿 曲安奈德 醋酸氟轻松 地塞米松 缓释系统 

分 类 号：R73[医药卫生—肿瘤]